Literature DB >> 25190756

Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice.

Wan-Chen Hsieh1, Ya-Ting Chuang2, I-Hsuan Chiang3, Shu-Ching Hsu4, Shi-Chuen Miaw5, Ming-Zong Lai6.   

Abstract

Emerging evidence indicates that innate immunodeficiency syndromes are linked to mutations in innate receptors and to specific infections. X-linked lymphoproliferative syndrome type-2 (XLP-2) is associated with deficiency in X-linked inhibitor of apoptosis protein (XIAP), with poorly understood molecular mechanisms. Here we showed that XIAP deficiency selectively impaired B-cell chronic lymphocytic leukemia/lymphoma 10 (BCL10)-mediated innate responses to dectin-1 ligands but did not affect responses to various Toll-like receptor agonists. Consequently, Xiap(-/-) mice became highly vulnerable on Candida albicans infection. The compromised early innate responses led to the persistent presence of C albicans and inflammatory cytokines in Xiap(-/-) mice. Furthermore, priming of Xiap(-/-) mice with the dectin-1 ligand curdlan alone resulted in XLP-2-like syndromes. Restoration of dectin-1-induced Rac1 activation and phagocytosis by resolvin D1, but not up-regulation of nuclear factor-κB, rescued Xiap(-/-) mice from C albicans lethal infection. Therefore, development of XLP-2 in XIAP-deficient patients could be partly due to sustained inflammation as a consequence of defective BCL10-dependent innate immunity toward specific pathogens. Importantly, our results suggest the potential therapeutic value of resolvin D1 in the treatment of XLP-2 and innate immunodeficiency syndromes.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25190756     DOI: 10.1182/blood-2014-03-564609

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease.

Authors:  Steven M Chirieleison; Rebecca A Marsh; Prathna Kumar; Joseph K Rathkey; George R Dubyak; Derek W Abbott
Journal:  J Biol Chem       Date:  2017-04-12       Impact factor: 5.157

Review 2.  The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Semin Immunol       Date:  2015-04-07       Impact factor: 11.130

3.  Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein.

Authors:  Siti Khadijah Kasani; Huei-Yin Cheng; Kun-Hai Yeh; Shu-Jung Chang; Paul Wei-Che Hsu; Shu-Yun Tung; Chung-Tiang Liang; Wen Chang
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

4.  Epstein Barr virus-mediated transformation of B cells from XIAP-deficient patients leads to increased expression of the tumor suppressor CADM1.

Authors:  Christine Engelmann; Patrick Schuhmachers; Hana Zdimerova; Sanamjeet Virdi; Mathias Hauri-Hohl; Jana Pachlopnik Schmid; Adam Grundhoff; Rebecca A Marsh; Wendy Wei-Lynn Wong; Christian Münz
Journal:  Cell Death Dis       Date:  2022-10-22       Impact factor: 9.685

Review 5.  How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease.

Authors:  Ole Haagen Nielsen; Eric Charles LaCasse
Journal:  Genet Med       Date:  2016-07-14       Impact factor: 8.822

Review 6.  Infection-induced inflammation from specific inborn errors of immunity to COVID-19.

Authors:  Cheng-Lung Ku; I-Ting Chen; Ming-Zong Lai
Journal:  FEBS J       Date:  2021-05-20       Impact factor: 5.622

Review 7.  Cancers Related to Immunodeficiencies: Update and Perspectives.

Authors:  Esmaeil Mortaz; Payam Tabarsi; Davod Mansouri; Adnan Khosravi; Johan Garssen; Aliakbar Velayati; Ian M Adcock
Journal:  Front Immunol       Date:  2016-09-20       Impact factor: 7.561

Review 8.  Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs).

Authors:  Rama Rathore; Jennifer E McCallum; Elizabeth Varghese; Ana-Maria Florea; Dietrich Büsselberg
Journal:  Apoptosis       Date:  2017-07       Impact factor: 4.677

Review 9.  Evolution of Our Understanding of XIAP Deficiency.

Authors:  Anne C A Mudde; Claire Booth; Rebecca A Marsh
Journal:  Front Pediatr       Date:  2021-06-17       Impact factor: 3.418

10.  IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells.

Authors:  Wan-Chen Hsieh; Tzu-Sheng Hsu; Ya-Jen Chang; Ming-Zong Lai
Journal:  Nat Commun       Date:  2018-01-31       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.